Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Baudax Bio, Inc. BXRXQ

 — 
0.00 0.00 NaN as of 25 Sep
Market cap
—
P/E
0.0×
Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Baudax Bio, Inc. (BXRXQ) Business Profile

Updated before January 2025

Company Overview

Baudax Bio, Inc. (BXRXQ) is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings. The company was founded in 2019 as a spin-off from Recro Pharma, Inc., with the goal of advancing its portfolio of non-opioid pain management and other acute care products. Headquartered in Malvern, Pennsylvania, Baudax Bio operates with a mission to address unmet medical needs in the acute care space, particularly in pain management and related therapeutic areas.

The company is led by a team of experienced professionals in the pharmaceutical and healthcare industries. As of the latest updates, the key leadership includes Gerri Henwood, who serves as the President and Chief Executive Officer. Henwood brings decades of experience in drug development and commercialization, having previously held leadership roles at Recro Pharma and other pharmaceutical companies. The leadership team also includes experts in clinical development, regulatory affairs, and commercial operations, ensuring a well-rounded approach to achieving the company’s strategic goals.

Core Business Segments

Baudax Bio focuses on the development and commercialization of products in the acute care pharmaceutical market. Its core business segments include:

Non-Opioid Pain Management

Baudax Bio’s flagship product is ANJESO® (meloxicam injection), a non-opioid, long-acting intravenous (IV) analgesic. ANJESO is designed to provide 24-hour pain relief with a single dose, making it a valuable option for managing moderate to severe pain in surgical and acute care settings. The product addresses the growing demand for non-opioid alternatives to pain management, particularly in light of the opioid crisis.

Acute Care Pharmaceuticals

In addition to ANJESO, Baudax Bio is actively exploring and developing other acute care pharmaceutical products. These include therapies aimed at improving patient outcomes in surgical and hospital settings. While specific pipeline products have not been disclosed in detail, the company’s focus remains on addressing critical unmet needs in acute care.

Licensing and Partnerships

Baudax Bio also engages in licensing and partnership opportunities to expand its product portfolio and market reach. By collaborating with other pharmaceutical companies and research organizations, the company aims to accelerate the development and commercialization of innovative therapies.

Business Model

Baudax Bio operates on a business model that integrates product development, commercialization, and strategic partnerships. The company generates revenue primarily through the sales of its flagship product, ANJESO, which is marketed to hospitals, surgical centers, and healthcare providers. Baudax Bio employs a targeted sales strategy, focusing on key decision-makers in acute care settings, such as anesthesiologists, surgeons, and hospital pharmacy directors.

To support its commercialization efforts, Baudax Bio invests in clinical research and real-world evidence studies to demonstrate the efficacy and safety of its products. The company also leverages digital marketing and educational initiatives to raise awareness about the benefits of non-opioid pain management solutions.

Strategic Direction

Baudax Bio’s strategic direction is centered on expanding its presence in the acute care market and addressing the growing demand for non-opioid pain management solutions. Key elements of the company’s strategy include:

  • Product Expansion: Baudax Bio aims to broaden its product portfolio by developing new therapies and exploring additional indications for ANJESO. The company is also evaluating opportunities to in-license or acquire complementary products.
  • Market Penetration: The company is focused on increasing the adoption of ANJESO in hospitals and surgical centers across the United States. This includes expanding its sales force and strengthening relationships with healthcare providers.
  • Global Expansion: While currently focused on the U.S. market, Baudax Bio is exploring opportunities to commercialize its products internationally through partnerships and licensing agreements.
  • Sustainability Goals: Baudax Bio is committed to addressing the opioid crisis by providing effective non-opioid alternatives for pain management. The company also aims to minimize its environmental impact through sustainable manufacturing and distribution practices.

Competitive Landscape

Baudax Bio operates in a competitive pharmaceutical market, facing competition from both large pharmaceutical companies and smaller specialty firms. Key competitors include:

  • Pacira BioSciences, Inc.: A leader in non-opioid pain management, known for its flagship product, EXPAREL®.
  • Heron Therapeutics, Inc.: Focused on developing therapies for pain management and postoperative care, including ZYNRELEF®.
  • Mallinckrodt Pharmaceuticals: Offers a range of acute care products, including pain management solutions.
  • Hospira (a Pfizer company): Provides a broad portfolio of injectable drugs and infusion technologies for acute care settings.

Baudax Bio differentiates itself through its focus on long-acting, non-opioid pain management solutions and its commitment to addressing unmet medical needs in acute care.

Risk Factors

Like any pharmaceutical company, Baudax Bio faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Market Dependence: The company’s revenue is heavily reliant on the success of ANJESO. Any challenges in market adoption or regulatory changes could significantly impact its financial performance.
  • Regulatory Risks: The pharmaceutical industry is highly regulated, and any delays or issues in obtaining regulatory approvals for new products could hinder the company’s growth.
  • Supply Chain Disruptions: Baudax Bio depends on third-party manufacturers and suppliers for the production of its products. Any disruptions in the supply chain could affect product availability.
  • Competition: The acute care market is highly competitive, with several established players offering similar products. This could limit Baudax Bio’s market share and pricing flexibility.
  • Financial Constraints: As a relatively small company, Baudax Bio may face challenges in securing the funding needed to support its research, development, and commercialization efforts.

Recent Developments

Baudax Bio has made significant strides in advancing its strategic goals. Recent developments include:

  • Increased Adoption of ANJESO: The company has reported growing adoption of ANJESO in hospitals and surgical centers, driven by positive clinical outcomes and real-world evidence.
  • Clinical Research: Baudax Bio continues to invest in clinical studies to expand the indications for ANJESO and demonstrate its benefits in various patient populations.
  • Corporate Restructuring: To streamline operations and focus on its core business, Baudax Bio has implemented cost-saving measures and organizational changes.
  • Partnerships: The company has entered into strategic partnerships to enhance its product development and commercialization capabilities.

Investment Considerations

Investors considering Baudax Bio should weigh the following strengths and risks:

Strengths

  • Innovative Product Portfolio: ANJESO offers a unique, long-acting, non-opioid solution for pain management, addressing a critical unmet need.
  • Experienced Leadership: The company is led by a team of seasoned professionals with a proven track record in the pharmaceutical industry.
  • Market Opportunity: The growing demand for non-opioid pain management solutions presents a significant market opportunity for Baudax Bio.

Risks

  • Revenue Dependence: The company’s financial performance is heavily reliant on the success of a single product, ANJESO.
  • Competitive Pressure: Baudax Bio faces competition from larger, well-established pharmaceutical companies.
  • Regulatory and Financial Risks: Delays in regulatory approvals and challenges in securing funding could impact the company’s growth.

Conclusion

Baudax Bio, Inc. is a promising player in the acute care pharmaceutical market, with a strong focus on non-opioid pain management solutions. While the company faces challenges such as market dependence and competition, its innovative product portfolio and strategic initiatives position it for growth. As the demand for non-opioid alternatives continues to rise, Baudax Bio is well-positioned to capitalize on this trend and expand its presence in the acute care market.